Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.32 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18259772 | 1.00 | LMNA (0.40) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| SCHEMBL27324 | 0.87 | AKR1B1 (0.33) | LMNAL3MBTL1TDP1AKR1B1 | |
| SCHEMBL28257916 | 0.78 | LMNA (0.43) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| SCHEMBL27870207 | 0.78 | LMNA (0.43) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| SCHEMBL11858560 | 0.78 | LMNA (0.43) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| SCHEMBL25264497 | 0.75 | LMNA (0.40) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| SCHEMBL16915296 | 0.75 | LMNA (0.40) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| SCHEMBL3645294 | 0.75 | LMNA (0.40) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| SCHEMBL19512303 | 0.75 | LMNA (0.40) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| SCHEMBL460069 | 0.75 | LMNA (0.40) | LMNAL3MBTL1TDP1PDE4AUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130184330-A1 | COMPOSITIONS AND METHODS FOR INDUCING CANCER CELL DEATH | UNIVERSITY OF MIAMI (US) | 2013-07-18 | — | — | US | claimed |
| WO-2012024234-A1 | COMPOSITIONS AND METHODS FOR INDUCING CANCER CELL DEATH | UNIVERSITY OF MIAMI (US) | 2012-02-23 | — | — | WO | claimed |
| US-20260009062-A1 | TRANSFER OF C2'-EPIMERIZED SUGARS TO THE AMPHOTERICIN B AGLYCONE | UNIV ILLINOIS (US) | 2026-01-08 | — | — | US | disclosed |
| CN-110373374-B | Methods and compositions for reducing antibody core fucosylation | 上海颢哲信息科技有限公司 | 2023-07-07 | — | — | CN | disclosed |
| WO-2019196697-A1 | METHOD AND COMPOSITION FOR REDUCING CORE FUCOSYLATION OF ANTIBODY | 上海颢哲信息科技有限公司 | 2019-10-17 | — | — | WO | disclosed |
| US-20130184330-A1 | COMPOSITIONS AND METHODS FOR INDUCING CANCER CELL DEATH | UNIVERSITY OF MIAMI (US) | 2013-07-18 | — | — | US | disclosed |
| WO-2012024234-A1 | COMPOSITIONS AND METHODS FOR INDUCING CANCER CELL DEATH | UNIVERSITY OF MIAMI (US) | 2012-02-23 | — | — | WO | disclosed |
| US-20100130434-A1 | Hexose Compounds to Treat Cancer | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-05-27 | — | — | US | disclosed |
| EP-1986660-A4 | HEXOSE COMPOUNDS TO TREAT CANCER | UNIV TEXAS (US) | 2009-08-26 | — | — | EP | disclosed |
| CN-101426508-A | Hexose compounds for the treatment of cancer | UNIV TEXAS (US) | 2009-05-06 | — | — | CN | disclosed |
| EP-1986660-A2 | HEXOSE COMPOUNDS TO TREAT CANCER | Board of Regents, The University of Texas System (US) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007101148-A2 | HEXOSE COMPOUNDS TO TREAT CANCER | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2007-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130434-A1 | Hexose Compounds to Treat Cancer | MAN2A1, FBP1, MAN2B1 | LMNA 4494/4885L3MBTL1 2549/4885TDP1 3705/4885 |
| US-20260009062-A1 | TRANSFER OF C2'-EPIMERIZED SUGARS TO THE AMPHOTERICIN B AGLYCONE | ERG28, SLC2A9, GALE | LMNA 1600/4885L3MBTL1 394/4885TDP1 4536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.